Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

ClinicalTrials.gov ID: NCT05595499

Public ClinicalTrials.gov record NCT05595499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Randomized Double-Blind Placebo-Controlled Study of Fisetin to Improve Physical Function in Breast Cancer Survivors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial tests whether fisetin works to improve physical function in women who have received chemotherapy for stage I-III breast cancer treatment. Fisetin is a naturally occurring substance that is found in strawberries and other foods. Fisetin eliminates cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that causes inflammation and damages nearby healthy cells. Studies have shown that chemotherapy causes a build-up of these senescent cells. Giving fisetin may eliminate senescent cells and improve physical function in postmenopausal women who have received chemotherapy for breast cancer.

Study identification

NCT ID: NCT05595499
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Enrollment: 88 participants

Conditions and interventions

Conditions

Interventions

Procedure · Drug · Other

Eligibility (public fields only)

Age range: Not listed
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 26, 2023
Primary completion: Aug 13, 2027
Completion: Aug 13, 2028
Last update posted: Jul 16, 2026

2023 – 2028

United States locations

U.S. sites: 7
U.S. states: 1
U.S. cities: 7

Facility	City	State	ZIP	Site status
UCLA Health Cancer Care in Alhambra	Alhambra	California	91801	Recruiting
UCLA Health Beverly Hills Primary & Specialty Care	Beverly Hills	California	90210	Recruiting
UCLA Health Burbank Primary & Specialty Care	Burbank	California	91505	Recruiting
City of Hope Comprehensive Cancer Center	Duarte	California	91010	Recruiting
UCLA / Jonsson Comprehensive Cancer Center	Los Angeles	California	90095	Recruiting
UCLA Health Primary Care in Marina del Rey	Marina del Rey	California	90292	Recruiting
UCLA Health Primary Care in Pasadena	Pasadena	California	91105	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05595499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 16, 2026 · Synced Sep 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05595499 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →